The Moffitt Cancer Center requests renewal of its NCI Cancer Center Support Grant (CCSG) for years 14-18. Moffitt is a free-standing cancer center whose sole mission is """"""""to contribute to the prevention and cure of cancer."""""""" Research activities are focused around five programs: Molecular Oncology &Drug Discovery;Immunology;Experimental Therapeutics;Cancer Epidemiology, and Health Outcomes &Behavior. Fourteen shared resources provide broad support for these programs and our faculty. Over the last grant period, Moffitt has made significant progress. Extramural funding increased from $54.0 million to 82.6 million. Membership increased from 135 to 156 including the recruitment of 67 new faculty. Over 1,900 peer-reviewed publications were generated over the last 5 years by Moffitt members. Clinical intervention trial accrual averaged 1,176 subjects per year. Facilities projects included an $87 million investment that added 36 hospital beds, 40,000 sf of faculty office space, 2 linear accelerators and related support space that included an expanded Clinical Research Unit. A nexus freezer system, a fully automated and robotic biorepository system with a capacity of over 2.4 million tubes, was installed. Moffitt has invested in strategic initiatives to enhance our basic, population and clinical researc to strengthen the research programs and spur collaboration. These major initiatives include Total Cancer Care, Moffitt's bold long-term initiative to realize personalized cancer care by incorporating information on molecular characterization of the host and tumor into treatment decisions. Other initiatives include investments in lung cancer, melanoma, imaging research, integrated mathematical oncology, health disparities and diversity, and education and training. The Moffitt proposal includes funding requests for 5 programs, 14 shared resources, and 7 staff investigators. The increased budget will provide critical resources to support and enhance the Center's infrastructure, particularly the shared resources. The institution, with generous support from the State, has developed a solid research infrastructure that has successfully supported a rapid increase in peer-reviewed funding and publications in a short amount of time. We believe our success to date represents a healthy return on investment made by the NCI and the state of Florida.

Public Health Relevance

The Cancer Center Support Grant will provide Moffitt with resources for critical infrastructure to reduce the cancer burden throughout Florida and across the United States. Moffitt's singular focus on cancer and obligation to serve as the State of Florida's cancer center positions the center to make significant contributions to the prevention and cure of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613439
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-02-18
Project End
2017-01-31
Budget Start
2014-03-03
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$2,637,094
Indirect Cost
$1,072,053
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556
Pamnani, Shitaldas J; Sudenga, Staci L; Rollison, Dana E et al. (2018) Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis 218:1219-1227
Poort, Hanneke; Meade, Cathy D; Knoop, Hans et al. (2018) Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs 41:E28-E37
Simmons, Vani N; Sutton, Steven K; Meltzer, Lauren R et al. (2018) Long-term outcomes from a self-help smoking cessation randomized controlled trial. Psychol Addict Behav 32:710-714
Dai, Juncheng; Li, Zhihua; Amos, Christopher I et al. (2018) Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis :

Showing the most recent 10 out of 1254 publications